# US 2015/0148294 A1 · Neuroendocrine Tumor Treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148294 A1
- Document ID: US20150148294A1
- Status: Published application
- Kind: A1
- Application number: 14/608,644
- Filed: 2015-01-29
- Published: 2015-05-28
- Earliest claimed: 2005-11-21
- Assignees: Novartis AG
- Inventors: Peter Wayne Marks; David Lebwohl
- Web page: https://patentgrep.com/patent/US20150148294A1

## CPC

- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 38/31: Somatostatins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.

## Claims

### Claim 1

A method for treating endocrine tumors, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.

### Claim 2

A method for inhibiting growth of endocrine tumors, comprising administering to a subject in need thereof a therapeutical effective amount of an mTOR inhibitor.

### Claim 3

A method for inhibiting or controlling endocrine tumors, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.

### Claim 4

A method for inducing endocrine tumor regression, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.

### Claim 5

A method for treating endocrine tumor invasiveness or symptoms associated with such tumor growth, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.

### Claim 6

A method for preventing metastatic spread of endocrine tumors or for preventing or inhibiting growth of micrometastasis, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.

### Claim 7

A method for the treatment of a disorder associated with endocrine tumors, comprising administering to a subject in need thereof a therapeutically effective amount of an mTOR inhibitor.

### Claim 8 (depends on 1)

A method according to claim 1, comprising administering in addition a therapeutically effective amount of at least one second drug substance.

### Claim 9 (depends on 8)

A method according to claim 8, wherein a second drug substance is somastatin or a somastatin analogue.

### Claim 10 (depends on 1)

The use of an mTOR inhibitor for the manufacture of a medicament for use in a method according to claim 1.

### Claim 11 (depends on 1, 10)

A method according to claim 1, or the use according to claim 10, wherein an mTOR inhibitor is selected from rapamycin or a rapamycin derivative.

### Claim 12 (depends on 10)

A method according to claim 10, wherein an mTOR inhibitor is 40-O-(2-hydroxyethyl)-rapamycin.
